Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Global Molecular Diagnostics Market To Reach $7.3B By 2019

Executive Summary

The global molecular diagnostics market will grow by $2.4 billion over the next five years according to a global market report from Medtech Insight. Major factors contributing to the healthy growth of this market include advances in technology, as well as the growing understanding of the human genome, pharmacogenomics and the relationship between genes and disease/infection.

You may also be interested in...



Danaher Buys Cepheid For $4bn, Citing Molecular Diagnostics Strength

Danaher is paying a 54% premium to acquire Cepheid, maker of the fully automated GeneXpert rapid genetic testing system. Cepheid will join Danaher's $5bn Diagnostics segment, which already includes Beckman Coulter, Leica Biosystems and Radiometer. Danaher executives cited Cepheid's large installed base and potential for growth and efficiency improvements as justifications for the deal. At least one analyst believes Danaher may be paying too much.

Oncopeptides’ Pepaxto Withdrawal Speeds Through In 7 Months Under Expedited Procedures

Of three accelerated approval drugs that have been ordered withdrawn to date, Pepaxto marks the shortest interval between the FDA drugs center's withdrawal proposal and the agency’s final order, suggesting that FDORA’s expedited withdrawal procedures helped move things along more quickly.

Accelerated Approval: US FDA’s Hammer Falls On Oncopeptides’ Pepaxto

Rejecting company’s appeal, CBER Director Peter Marks says the multiple myeloma drug should be withdrawn because its confirmatory trial failed to verify clinical benefit and evidence demonstrates the drug is not safe and effective for its current indication.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035954

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel